Scientific article
OA Policy
French

Nécrose rétinienne aiguë due au virus de la varicelle et du zona et vaccin recombinant contre le zona

Other titleVaricella-zoster virus (VZV) acute retinal necrosis and recombinant zoster vaccine
Published inRevue médicale suisse, vol. 18, no. 777, p. 714-717
Publication date2022-04-13
Abstract

Varicella zoster virus (VZV) is responsible for chickenpox. Like all herpes viruses, after primary infection it enters into latency and can be reactivated afterwards. Many forms of symptomatic reactivation of VZV exist including acute retinal necrosis (ARN), an ophthalmic emergency which can lead to blindness. ARN is treated starting with high-dose intravenous acyclovir then with oral valaciclovir for a total duration of up to 3 months. Symptomatic reactivations of VZV are public health issues. The new Swiss 2022 vaccination plan includes the recombinant vaccine Shingrix. It effectively prevents VZV symptomatic reactivations even in elderly and immuno suppressed patients.

Keywords
  • Aged
  • Chickenpox / prevention & control
  • Chickenpox Vaccine / therapeutic use
  • Herpes Zoster / drug therapy
  • Herpes Zoster / prevention & control
  • Herpes Zoster Vaccine / therapeutic use
  • Herpesvirus 3, Human / physiology
  • Humans
  • Retinal Necrosis Syndrome, Acute / drug therapy
  • Vaccines, Synthetic / therapeutic use
Citation (ISO format)
TIRAT, William Robert, SCHIBLER, Manuel. Nécrose rétinienne aiguë due au virus de la varicelle et du zona et vaccin recombinant contre le zona. In: Revue médicale suisse, 2022, vol. 18, n° 777, p. 714–717. doi: 10.53738/REVMED.2022.18.777.714
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1660-9379
83views
387downloads

Technical informations

Creation08/02/2023 07:52:34
First validation02/08/2023 14:20:32
Update10/02/2026 08:08:22
Status update10/02/2026 08:08:22
Last indexation10/02/2026 08:09:37
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack